

Xiaofei Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7333394/publications.pdf>

Version: 2024-02-01

24
papers

624
citations

840119

11
h-index

642321

23
g-index

24
all docs

24
docs citations

24
times ranked

897
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	0.8	2
2	Metabolism and Disposition of [¹⁴ C]Pevonedistat, a First-In-Class NEDD8-Activating Enzyme Inhibitor, After Intravenous Infusion to Patients With Advanced Solid Tumors. <i>Drug Metabolism and Disposition</i> , 2022, , DMD-AR-2022-000842.	1.7	1
3	Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 488-498.	1.2	15
4	Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. <i>Clinical and Translational Science</i> , 2021, 14, 1069-1081.	1.5	9
5	Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. <i>Journal of Clinical Pharmacology</i> , 2021, , .	1.0	3
6	Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Drug Metabolism and Disposition</i> , 2020, 48, 217-229.	1.7	11
7	Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2568-2579.	1.1	13
8	Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1204-1215.	1.0	3
9	Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1464-1473.	1.1	9
10	Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 666-673.	1.2	5
11	Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2018, 36, 248-258.	1.2	16
12	Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 35-51.	1.1	13
13	Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2018, 36, 240-247.	1.2	5
14	Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. <i>Drugs in R and D</i> , 2016, 16, 45-52.	1.1	10
15	Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 336-347.	1.0	27
16	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015, 33, 942-953.	1.2	27
17	Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 563-572.	0.3	8
18	Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2014, 32, 489-499.	1.2	67

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. <i>Journal of Clinical Oncology</i> , 2014, 32, 44-50.	0.8	185
20	Translational Exposureâ€Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2170-2183.	1.9	29
21	Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. <i>Investigational New Drugs</i> , 2014, 32, 1181-1187.	1.2	34
22	Abstract B216: Mass balance, routes of excretion and pharmacokinetics of investigational oral [¹⁴ C]alisertib (MLN8237) in patients with advanced solid tumors or lymphoma.. <i>Molecular Cancer Therapeutics</i> , 2013, 12, B216-B216.	1.9	4
23	Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2012, 127, 63-69.	0.6	128
24	Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2597-2597.	0.8	0